Dr Javier J Zulueta enters
the boardroom as Chief Medical Officer, Pulmonology with the potential of changing
the lung cancer survival curve in a single generation
Back
New
York, August 20, 2025: Qure.ai has appointed Dr Javier J Zulueta, previously Professor of
Medicine at the Icahn School of Medicine at Mount Sinai in New York and
Pulmonary Division Chief at Mount Sinai Morningside Hospital, to the new
position of Chief Medical Officer, Pulmonology.
The
role will dovetail his deep clinical insight to the ongoing research &
development in lung health AI and digital health care coordination solutions to
bolster Qure.ai’s pace of business expansion in the USA and Europe.
Prashant Warier,
Founder and CEO of Qure.ai states, “We warmly welcome Dr J Zulueta to bring his
unmatched global expertise in lung cancer screening and management to Qure.ai.
His knowledge will be instrumental in the ongoing strategic development of our
Lung Cancer Suite of AI-powered solutions and to drive clinical deployments in
health systems and hospitals at scale.”
Dr
Javier J Zulueta, Chief Medical Officer at Qure.ai states, “Lung cancer remains
the deadliest cancer in the world, not because we can’t treat it, but because
we find it too late. We stand at a pivotal moment in clinical and technology
disruption where the power of AI can be harnessed safely to turn small incidental
lung nodule findings into lifesaving interventions. Joining Qure.ai puts me at
the epicentre of this change – we have the potential to change the survival
curve in a single generation.”
Dr
Zulueta brings more than three decades of experience as a physician, scientist,
academician and pioneer in interventional pulmonology, lung cancer screening
and pulmonary nodule / disease management. Prior to Mount Sinai, he founded and led the
inaugural Department of Respiratory Medicine at Clinica Universidad de Navarra
in Pamplona, Spain’s premier medical school, where he launched the country’s
first lung cancer screening program as Principal Investigator of the International
Early Lung Cancer Action Program (IELCAP). His passion in the advancement of early lung
cancer detection through medical technology has also led to him taking a number
of past roles with commercial companies as an Advisory Board Member.
The
new CMO appointment builds on a rapid pace of business scaling for Qure.ai in
the USA. At the start of 2025 it appointed Jim Mercadante as Chief Commercial
Officer, followed by a dozen business development, sales and strategic account
management appointments across the States. Recently, Qure.ai was also recognized
as a TIME100 Most Influential Company 2025 for the use of AI to reshape access
and diagnosis of high-burden diseases worldwide. Qure.ai is deployed in more
than 100 countries and has 18 FDA cleared findings.
